AML, safety data for magrolimab help Forty Seven shares regain ground

After disappointing investors with its first data on anti-CD47 mAb magrolimab in May, Forty Seven gained $1.20 (18%) to $8.01 on Wednesday with updated data showing slight improvements in AML response rates and a consistent safety profile.

In an abstract released ahead of next month’s American Society of Hematology (ASH) meeting, Forty Seven Inc. (NASDAQ:FTSV) reported updated Phase Ib data on the combination of magrolimab and Vidaza azacitidine from Celgene Corp. (NASDAQ:CELG) in myelodysplastic syndrome (MDS) and first-line acute myelogenous leukemia (AML). ...